Market Overview 2023-2028:
The global human insulin market size reached US$
45.0 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$
68.0 Billion by 2028, exhibiting a growth rate (CAGR) of
6.48% during 2023-2028.
Human insulin (HI) is a short-acting form of insulin used to treat hyperglycemia caused by type 1 and type 2 diabetes. It is produced by recombinant DNA technology and identical to endogenously made insulin. It is used to take the place of insulin generally produced by the body and aids in insulating sugar from the blood into other body tissues, wherein it is utilized for energy. It induces lower titers of circulating insulin antibodies and minimizes skin reactions. At present, manufacturers are introducing an inhalable form intended to be used as a bolus meal-time insulin.
Human Insulin Market Trends:
The increasing prevalence of diabetes on account of sedentary lifestyles, unhealthy dietary patterns, and high-stress levels represents one of the major factors positively influencing the demand for HI around the world. Moreover, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. In addition, key players are introducing pen devices and safety pen needles to administer HI in the body. It assists in minimizing discomfort and reducing the risks of injuries, infections, and bloodborne pathogen transmission. Apart from this, the growing public awareness about the benefits of using HI and the increasing health consciousness among individuals is driving the market. Besides this, significant improvements in the healthcare infrastructure and extensive research and development (R&D) activities in the field of biotechnology conducted by leading industry players are creating a positive outlook in the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global human insulin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product type, distribution channel and disease type.
Breakup by Product Type:
- Human Insulin Analogs and Biosimilars
- Rapid Acting
- Long Acting
- Human Insulin Biologics
- Short Acting
- Intermediate Acting
- Delivery Devices
- Reusable Pens
- Disposable Pens
- Pen Needles
- Standard Pen Needles
- Safety Pen Needles
Breakup by Distribution Channel:
- Retail Pharmacies
- Hospital Pharmacies
- Online Retail Stores
Breakup by Disease Type:
- Type I Diabetes
- Type II Diabetes
Breakup by Region:
- North America
- Asia Pacific
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined with some of the key players being B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited, Ypsomed AG, etc.
|Base Year of the Analysis
||Product Type, Distribution Channel, Disease Type, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||B. Braun Melsungen AG, Becton, Dickinson and Company (BD), Biocon, Eli Lilly and Company, Gulf Pharmaceutical Industries (Julphar), Novo Nordisk A/S, Pfizer Inc., Groupe Sanofi, SEDICO Co., Wockhardt Limited and Ypsomed AG
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global human insulin market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global human insulin market?
- What are the key regional markets?
- What is the breakup of the market based on the product type?
- What is the breakup of the market based on the drug type?
- What is the breakup of the market based on the delivery devices?
- What is the breakup of the market based on the distribution channel?
- What is the breakup of the market based on the disease type?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global human insulin market and who are the key players?
- What is the degree of competition in the industry?